BioCentury
ARTICLE | Financial News

ALS newco QurAlis launches

April 5, 2018 4:18 PM UTC

Amyotrophic lateral sclerosis company QurAlis Corp. (Cambridge, Mass.) debuted with seed funding from MP Healthcare Venture Management, Amgen Ventures and Alexandria Venture Investments. QurAlis CEO Kasper Roet declined to disclose financial terms.

QurAlis is targeting three ALS subtypes. The company has two preclinical therapeutic programs, and is developing a device to remove toxic proteins from the brain and cerebral spinal fluid...